Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A Tim-3 small molecule inhibitor is a class of small molecule compounds designed to target and inhibit T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), an immune checkpoint receptor. Tim-3 is expressed on various immune cells, including T cells, natural killer (NK) cells, and macrophages. In the context of pulmonary fibrosis, Tim-3 inhibition has been shown to regulate macrophage polarization, specifically suppressing the activation of Stat3 signaling pathways, which in turn inhibits the activation and proliferation of fibroblasts. In oncology, small molecule inhibitors of Tim-3 block its interaction with ligands such as galectin-9, phosphatidylserine (PtdSer), HMGB1, and CEACAM1, thereby restoring T-cell and NK-cell function and enhancing anti-tumor immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tim-3 small molecule inhibitor.